CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
Marion Drouin,Javier Saenz,Vanessa Gauttier,Berangere Evrard,Geraldine Teppaz,Sabrina Pengam,Caroline Mary,Ariane Desselle,Virginie Thepenier,Emmanuelle Wilhelm,Emmanuel Merieau,Camille Ligeron,Isabelle Girault,Maria-Dolores Lopez,Cynthia Fourgeux,Debajyoti Sinha,Irene Baccelli,Aurelie Moreau,Cedric Louvet,Regis Josien,Jeremie Poschmann,Nicolas Poirier,Elise Chiffoleau
DOI: https://doi.org/10.1126/sciadv.abo7621
IF: 13.6
2022-11-19
Science Advances
Abstract:Tumors exploit numerous immune checkpoints, including those deployed by myeloid cells to curtail antitumor immunity. Here, we show that the C-type lectin receptor CLEC-1 expressed by myeloid cells senses dead cells killed by programmed necrosis. Moreover, we identified Tripartite Motif Containing 21 (TRIM21) as an endogenous ligand overexpressed in various cancers. We observed that the combination of CLEC-1 blockade with chemotherapy prolonged mouse survival in tumor models. Loss of CLEC-1 reduced the accumulation of immunosuppressive myeloid cells in tumors and invigorated the activation state of dendritic cells (DCs), thereby increasing T cell responses. Mechanistically, we found that the absence of CLEC-1 increased the cross-presentation of dead cell–associated antigens by conventional type-1 DCs. We identified antihuman CLEC-1 antagonist antibodies able to enhance antitumor immunity in CLEC-1 humanized mice. Together, our results demonstrate that CLEC-1 acts as an immune checkpoint in myeloid cells and support CLEC-1 as a novel target for cancer immunotherapy.
multidisciplinary sciences